Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“25 years of TKIs in CML – how I treat CML-CP today
- BCR-ABL1 drives disease; all frontline TKIs deliver excellent survival.
- Choice ≠ OS → it’s about risk (ELTS>Sokal), comorbidities, toxicity, and DMR/TFR goals.
- Imatinib = safest CV, slowest.
2G TKIs/asciminib = faster, deeper responses (watch toxicity).
Nilotinib → vascular risk. Dasatinib → lung toxicity. - Asciminib → allosteric, avoid b2a3/b3a3.
The art is matching the right TKI to the right patient.”
Title: How I individualize frontline treatment for chronic-phase CML
Authors: Ariel Leyte-Vidal, Neil P. Shah
You can read the Full Article in Blood.
More posts featuring Talha Badar.
